Skip to main content
Fig. 2 | BMC Pharmacology and Toxicology

Fig. 2

From: Safety, tolerability, and pharmacokinetics of repeated oral doses of 2-hydroxybenzylamine acetate in healthy volunteers: a double-blind, randomized, placebo-controlled clinical trial

Fig. 2

2-Hydroxybenzylamine (2-HOBA) metabolite does not inhibit cyclooxygenases. Urinary metabolites of a) prostaglandin E2 (PGE-M), b) thromboxane B2 (TxB2-M), and c) prostacyclin (PGI-M) were measured by LC-ESI/MS/MS before and after treatment. There were no significant changes in urinary metabolite concentration (mixed-effects model, n ≥ 5)

Back to article page